FDA Approved: UNLOXCYT — Original Application (Sun Pharmaceutical Industries, Inc.)

View source ↗

Summary

FDA approves UNLOXCYT (cosibelimab) in an original application from Sun Pharmaceutical for metastatic cutaneous squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• UNLOXCYT (COSIBELIMAB)

Snippet

ORIG AP for UNLOXCYT (COSIBELIMAB)